Scarica l'app Stockscreener
0.3915
5.55%
0.0206
Precedente Chiudi:
$0.3709
Aprire:
$0.37
Volume 24 ore:
1.65M
Relative Volume:
2.73
Capitalizzazione di mercato:
$26.54M
Reddito:
$9.14M
Utile/perdita netta:
$-124.31M
Rapporto P/E:
-0.409
EPS:
-0.9573
Flusso di cassa netto:
$-125.43M
1 W Prestazione:
-48.04%
1M Prestazione:
-46.84%
6M Prestazione:
-63.75%
1 anno Prestazione:
-79.29%
Intervallo 1D:
$0.3647
$0.4168
Intervallo di 1 settimana:
$0.3506
$0.7699
Portata 52W:
$0.3506
$2.57
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Nome
Tscan Therapeutics Inc
Settore
Industria
Telefono
857-399-9500
Indirizzo
830 WINTER STREET, WALTHAM
Compare TCRX vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TCRX
Tscan Therapeutics Inc
|
0.3915 | 52.61M | 9.14M | -124.31M | -125.43M | -0.9573 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-05-16 | Iniziato | BTIG Research | Buy |
| 2024-05-13 | Iniziato | Needham | Buy |
| 2023-06-22 | Iniziato | Wedbush | Outperform |
Tscan Therapeutics Inc Borsa (TCRX) Ultime notizie
Tscan Therapeutics Inc (NASDAQ: TCRX) Stock Price, News & Analysis - Kalkine
Amgen abandoning $500M+ Crohn’s collab won’t derail TScan’s pipeline strategy - Fierce Biotech
Amgen cans its TScan partnership; Amylyx reveals $350M offering - Endpoints News
TScan Therapeutics Faces Loss of Key Amgen Partnership - TipRanks
TScan TherapeuticsAmgen To Terminate Research Collaboration And License Agreement With TScan TherapeuticsSEC Filing - TradingView
TScan (NASDAQ: TCRX) loses Amgen Crohn’s collaboration - Stock Titan
TScan Therapeutics (TCRX) Edges Higher, Holding Support at $0.74Up Down Volume - vinanet.vn
Lynx1 Capital discloses 13.1% position in TScan Therapeutics (TCRX) common stock - Stock Titan
Biotechnology Value Fund group (TCRX) reports 9.99% TScan ownership with large warrants - Stock Titan
Equities Analysts Set Expectations for TCRX FY2026 Earnings - MarketBeat
H.C. Wainwright reiterates Tscan Therapeutics stock rating at buy By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Tscan Therapeutics stock rating at buy - Investing.com
Tscan Therapeutics earnings beat by $0.03, revenue fell short of estimates - Investing.com Nigeria
TScan Therapeutics, Inc. (TCRX) stock price, news, quote and history - uk.finance.yahoo.com
TScan Therapeutics, Inc. (NASDAQ:TCRX) Given Average Rating of "Hold" by Brokerages - MarketBeat
TScan Therapeutics (NASDAQ:TCRX) Releases Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
TScan Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
TScan Therapeutics, Inc. (TCRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
TScan Therapeutics Q2 Results: Sales Fall 66% YoY, EPS Misses - scanx.trade
TScan Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Form 8K Tscan Therapeutics Inc For: 12 August By Investing.com - Investing.com Nigeria
TScan Therapeutics, Inc. 2Q 2026: Revenue $1.05M, Net loss $30.36M, EPS $(0.23) — 10-Q Summary - TradingView
TScan Therapeutics (TCRX) narrows loss but warns on going-concern outlook and debt - Stock Titan
TScan Therapeutics reports Q2 2026: $1.1M revenue, $30.4M net loss, cash $100.2M - TradingView
TScan Therapeutics Reports $30.4 Million Q2 Net Loss - Quiver Quantitative
TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
TScan Therapeutics (TCRX) narrows Q2 2026 loss and doses first patient in Phase 3 ALLOHA-2 trial - Stock Titan
TScan Therapeutics Q2 net loss narrows on lower R&D costs - TradingView
TScan Therapeutics Reports First Patient Dosed in Phase 3 ALLOHA-2 Study and Second-Quarter 2026 Results - Quiver Quantitative
TScan Therapeutics (TCRX) Edges Higher as Price Holds Above Key $0.73 SupportIndex Put Call - Vinanet
TScan Therapeutics Inc (TCRX) Stock News Today - TradingKey
TScan Therapeutics Inc (TCRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TScan Therapeutics Inc expected to post a loss of 21 cents a shareEarnings Preview - TradingView
TScan Therapeutics (TCRX) Climbs 4.5% to $0.77, Testing Key Resistance ZoneSweep Order Flow - vinanet.vn
Short Interest in TScan Therapeutics, Inc. (NASDAQ:TCRX) Expands By 95.5% - MarketBeat
TScan doses first patient in phase 3 AML, MDS trial By Investing.com - Investing.com Nigeria
TScan Therapeutics Announces First Patient Dosed in Phase 3 - GlobeNewswire
TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies - The Manila Times
TScan Therapeutics Inc (TCRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TScan Therapeutics Inc (TCRX) Institutional Confidence - TradingKey
TScan Therapeutics Inc (TCRX) Income Statement - TradingKey
TScan Therapeutics Inc (TCRX) Cash Flow - TradingKey
TScan Therapeutics Inc (TCRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TScan Therapeutics Inc (TCRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TCRX|TScan Therapeutics Inc|Price:0.765|Chg%:-0.029 - TradingKey
TScan Therapeutics Inc (TCRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TScan Therapeutics Inc (TCRX) Balance Sheet - TradingKey
TScan Therapeutics, Inc. Revenue Breakdown – NASDAQ:TCRX - TradingView
TScan Therapeutics Inc (TCRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TCRX|TScan Therapeutics Inc|Price:0.782|Chg%:-0.012 - TradingKey
Tscan Therapeutics Inc Azioni (TCRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Tscan Therapeutics Inc Azioni (TCRX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 10% Owner |
Dec 22 '25 |
Buy |
0.90 |
75,500 |
67,950 |
8,012,916 |
| Lynx1 Capital Management LP | 10% Owner |
Dec 23 '25 |
Buy |
0.90 |
6,232 |
5,602 |
8,019,148 |
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):